If you’ve spent any time in the longevity world, you’ve heard about NAD+. It’s the molecule David Sinclair built half his career around. It’s the reason your favorite biohacker is taking $80/month NMN supplements. It’s the IV drip celebrities pay $700 a session for.
But here’s the question almost no one is asking clearly: when researchers actually run controlled trials on NAD+ supplementation, what do they find?
The short answer: real, measurable changes at the cellular level — but the bigger anti-aging benefits people are paying for? The evidence is mixed at best. Here’s the full picture.
What NAD+ actually does
NAD+ stands for nicotinamide adenine dinucleotide. (You don’t need to remember that.) What you do need to remember:
- It’s a molecule your body uses for hundreds of essential cellular reactions
- It’s required to convert food into energy in your cells (specifically in mitochondria)
- It’s the fuel for two protein families called sirtuins and PARPs — both of which are critical for DNA repair, cellular stress response, and “longevity signaling”
In short: without enough NAD+, your cells can’t repair themselves as well, can’t generate energy as efficiently, and can’t fight aging at the molecular level.
The age problem: NAD+ levels decline
Here’s where it gets interesting. NAD+ levels decline with age — substantially.
- In your 20s: NAD+ levels are at their peak
- By age 60: NAD+ levels in many tissues are about half of what they were
- This decline correlates strongly with markers of cellular aging — mitochondrial dysfunction, DNA damage accumulation, inflammation
The hypothesis that built the entire NAD+ supplement industry: if low NAD+ contributes to aging, then putting it back should slow aging.
NMN vs NR vs IV NAD+: the delivery options
You can’t just swallow NAD+ — the molecule is too large to absorb directly through your gut. So researchers have studied four different “precursors” — smaller molecules your body converts into NAD+:
- NMN (nicotinamide mononucleotide) — most popular in supplements
- NR (nicotinamide riboside) — also widely sold, including a branded version called Niagen
- Niacin — old-school B3 vitamin, very cheap, decent NAD+ booster
- Nicotinamide — present in food
Plus three direct delivery options:
- IV NAD+ — full-strength NAD+ delivered via infusion
- Subcutaneous NAD+ — injection under the skin (the form many research catalogs carry)
- Oral NAD+ — generally considered ineffective due to absorption issues
What NAD+ research actually shows
A massive systematic review published in early 2026 looked at every human and rodent NAD+ trial published between 2010 and October 2025 — 113 studies in total, 33 of which were human trials. The findings, in plain English:
What’s well established
- Oral NMN and NR reliably increase circulating NAD+ levels in the blood
- They’re well tolerated, with minimal side effects over weeks to months of use
- They show strong effects in rodent studies — improved metabolism, reduced inflammation, better mitochondrial function
What’s mixed or unclear
- Effects on actual functional outcomes in humans (energy, cognition, physical performance) are inconsistent across studies
- Many trials are small (often fewer than 50 participants), short (8–12 weeks), and not standardized
- Whether boosting NAD+ in healthy people changes anything meaningful is genuinely unknown
What we don’t know yet
- Whether IV or subcutaneous NAD+ delivers any benefit beyond what oral precursors provide (this hasn’t been tested in any rigorous controlled trial)
- Long-term safety at the doses people are using
- Whether NAD+ supplementation could be harmful in people with cancer (some researchers have raised the concern that NAD+ may support cancer cell growth)
Where NAD+ does seem to clearly help
A few specific use cases have stronger evidence:
- Premature aging diseases. In rare diseases like Cockayne syndrome where NAD+ levels are pathologically low, supplementation has shown clear clinical benefit.
- Skeletal muscle in older adults. Multiple trials have shown improvements in muscle metabolism and physical performance markers in older participants.
- Insulin sensitivity in some populations — particularly in pre-diabetic women.
- Neurodegenerative disease research. Several active Parkinson’s and Alzheimer’s trials are testing whether NAD+ precursors can slow disease progression.
Where the NAD+ hype has run ahead of the evidence
A few things commonly claimed about NAD+ that the evidence does NOT clearly support:
- “Reverses biological aging”
- “Restores energy in healthy people”
- “Improves cognition in healthy people”
- “Adds years to your life”
The honest version: NAD+ does important things at the cellular level, and supplementation does measurably increase NAD+ in your blood. Whether that translates to feeling younger, living longer, or being healthier — that’s a much harder question, and the evidence is genuinely mixed.
The 2026 NAD+ research direction
Here’s where the field is heading, based on emerging literature:
Stopping the leak, not just adding fuel. A new wave of research is targeting CD38 (an enzyme that destroys NAD+) and NAMPT (an enzyme that creates NAD+) — trying to fix WHY your body’s NAD+ drops, rather than just supplementing.
Better delivery systems. Liposomal formulations and combination supplements (NAD+ precursors paired with sirtuin activators or other co-factors) are showing better effects than precursors alone in some trials.
Disease-specific trials. Most ongoing 2026 trials are testing NAD+ in specific conditions — Parkinson’s, Alzheimer’s, heart failure, long COVID — rather than general “anti-aging” applications.
Practical takeaways for NAD+ research
If you’re researching NAD+ as a compound:
- The biochemistry is real. Cellular benefits are well-documented at the molecular level.
- Direct subcutaneous NAD+ administration is what most research catalogs offer, and it bypasses the absorption problem oral precursors face.
- The big “anti-aging” claims you’ll see online are running ahead of the actual clinical evidence.
- For specific conditions where NAD+ is depleted (older adults, certain diseases), there’s better evidence than for general healthy-person use.
The field is moving fast, but it’s not at the finish line yet. Most ongoing trials will read out by 2028, which should give us much clearer answers. (For broader context on the regulatory shifts affecting peptide and longevity compound research in 2026, see our breakdown of the FDA peptide reclassification.)
Strictly for qualified research use only. Nothing in this article should be construed as medical advice.
